全文获取类型
收费全文 | 2548篇 |
免费 | 144篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 119篇 |
妇产科学 | 29篇 |
基础医学 | 331篇 |
口腔科学 | 47篇 |
临床医学 | 259篇 |
内科学 | 524篇 |
皮肤病学 | 44篇 |
神经病学 | 176篇 |
特种医学 | 78篇 |
外科学 | 413篇 |
综合类 | 62篇 |
一般理论 | 4篇 |
预防医学 | 170篇 |
眼科学 | 38篇 |
药学 | 131篇 |
中国医学 | 19篇 |
肿瘤学 | 229篇 |
出版年
2023年 | 16篇 |
2022年 | 17篇 |
2021年 | 79篇 |
2020年 | 51篇 |
2019年 | 85篇 |
2018年 | 100篇 |
2017年 | 57篇 |
2016年 | 60篇 |
2015年 | 66篇 |
2014年 | 97篇 |
2013年 | 117篇 |
2012年 | 173篇 |
2011年 | 175篇 |
2010年 | 101篇 |
2009年 | 72篇 |
2008年 | 138篇 |
2007年 | 136篇 |
2006年 | 138篇 |
2005年 | 129篇 |
2004年 | 119篇 |
2003年 | 106篇 |
2002年 | 85篇 |
2001年 | 74篇 |
2000年 | 46篇 |
1999年 | 65篇 |
1998年 | 19篇 |
1997年 | 21篇 |
1996年 | 11篇 |
1995年 | 13篇 |
1994年 | 21篇 |
1993年 | 11篇 |
1992年 | 32篇 |
1991年 | 19篇 |
1990年 | 16篇 |
1989年 | 17篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 22篇 |
1985年 | 28篇 |
1984年 | 10篇 |
1983年 | 12篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1974年 | 7篇 |
1973年 | 8篇 |
1972年 | 8篇 |
1970年 | 7篇 |
1966年 | 7篇 |
排序方式: 共有2696条查询结果,搜索用时 156 毫秒
41.
42.
This report describes a case of manic symptoms induced by olanzapine in an 85-year-old female with a 3 year history of delusional disorder. She was treated in the past with trifluoperazine and risperidone. Symptoms were severe enough to require detention in hospital. Florid manic symptoms resolved two weeks after stopping olanzapine while only using 1 mg of haloperidol as required. 相似文献
43.
44.
45.
46.
47.
48.
Amit Goel Dharmendra Singh Bhadauria Anupma Kaul Narayan Prasad Amit Gupta Raj Kumar Sharma Praveer Rai Rakesh Aggarwal 《Indian journal of gastroenterology》2017,36(2):137-140
In recent past, direct-acting anti-viral drugs (DAAs) have become the standard of care for the treatment of hepatitis C virus (HCV) infection. However, the experience with the use of these drugs in Indian renal transplant recipients is limited. We retrospectively reviewed our experience with DAA-based treatment for HCV infection in such patients. Between April 2015 and December 2016, six adults (median age 41 [range 34–52] years, male 5; GT1 2, GT3 3, and GT4 1; including three with prior failed interferon-based treatment) had received genotype-guided, DAA-based anti-HCV treatment 1 to 158 (median 15) months after renal transplantation. Of them, four completed the planned 24-week treatment without any significant adverse event. One of them had increase in serum creatinine after 16 weeks of treatment with sofosbuvir and daclatasvir, with acute interstitial nephritis on kidney biopsy; his renal function improved on stopping the drugs. The other patient had preexisting mild renal dysfunction, which worsened after 8 weeks of sofosbuvir-ledipasvir treatment; this did not reverse on stopping treatment. All the six patients achieved undetectable HCV RNA after 4 weeks of treatment and also achieved sustained virologic response, i.e. lack of detectable HCV RNA in serum 12 weeks after stopping treatment. Overall, DAA-based treatment was effective in treating HCV infection in our renal transplant recipients; however, caution and monitoring of renal function during such treatment is advisable in patients who have additional factors that predispose to renal injury. 相似文献
49.
Purpose: Despite the prevalence and cost of traumatic brain injury related disabilities, there is paucity in the literature on modern approaches to pharmacotherapy. Medications may promote recovery by enhancing some neurological functions without impacting others. Herein we discussed the role of
bromocriptine in neurorehabilitation for patients with traumatic brain injury.
Methods: A cohort comprising of 36 selective nonsurgical cases of traumatic brain injury in minimally
conscious state were enrolled in the study. After hemodynamic stability, bromocriptine was given at
paediatric dose of 3.75 mg/d and adult dose of 7.5 mg/d. It was administered through a naso-gastric (NG) feeding tube in the patients with minimally conscious state, then changed to oral route after proper swallowing and good gag reflex were ensured in the patient. The drug was slowly reduced over three weeks after neurological improvement in the patients. Positive result was determined by improvd GCS score of 2 and motor power by at least 1 British Medical Council (BMC) motor score. Improvement of deficits was evaluated in terms of fluency of speech for aphasia, task switching, digit span double tasking and trail-making test for cognition and attention, and functional independence measure score for motor functioning and self-independence.
Results: Accelerated arousal was seen in 47.0% of cases (8/17) in 4e40 days. In 41.2% of cases (7/17), Glasgow outcome score (GOS) was improved to 4/5 in 90 days. Improvement in hemiparesis by at least 1 BMC score was seen in 55.6% of cases (5/9) in 40 days. Aphasia was improved in 80% of cases (4/5) in 7-30 days. Moderate improvement in cognitive impairment was seen in 66.7% of cases (2/3) in 14e20 days. Improvement in memory was observed in 50% of cases (1/2) in over 30 days. No cases were withdrawn from the study because of adverse reactions of the drug. There was no mortality in the study group.
Conclusion: Bromocriptine improves neurological sequelae of traumatic brain injury as well as the
overall outcome in the patients. If medication is given to promote recovery and treat its associated
disabilities, clinicians should thoroughly outline the goals and closely monitor adverse effects. 相似文献
50.